Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736509 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
A Phase 3 study, sponsored by Axsome Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 139
- Enrollment target
NCT06736509 is a Phase 3 study that was terminated before completion, run by Axsome Therapeutics. The registered enrollment target is 139 participants.
The verdict
NCT06736509, a Phase 3 study, was terminated before completion, sponsored by Axsome Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 139 participants
- Enrollment target
Study Summary
The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
Interventions
- DRUG AXS-05 (dextromethorphan-bupropion)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06736509
The ClinicalTrials.gov registry entry for NCT06736509 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AXS-05 (dextromethorphan-bupropion) is the first listed.
NCT06736509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06736509 about?
NCT06736509 is a clinical study titled "An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study". The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.
What is the current status of trial NCT06736509?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 139 participants. The study started on 2024-11-21. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06736509?
The interventions under investigation include: AXS-05 (dextromethorphan-bupropion) (DRUG).
Who is sponsoring clinical trial NCT06736509?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.